Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that preclinical data from the Company’s NeuVax™ (nelipepimut-S) program is being presented today at the Progress in Vaccination Against Cancer (PIVAC) Conference in Winchester, UK.  NeuVax contains the immunodominant peptide derived from the extracellular region of the HER2 protein, which is expressed in ovarian and pancreatic cancers as well as in breast cancer.

The poster, entitled, “Preclinical study on the efficacy of NeuVax peptide vaccine against human Her2+/ HLA-A2.1+ ovarian and pancreatic cancer,” demonstrated the results of HLA-A2 transgenic mice that were immunized with NeuVax (E75) mixed with recombinant mouse GM-CSF (NeuVax mice). As control, a group of mice received GM-CSF alone (control mice). CD8+ T cells purified from the spleens of HLA-A2 transgenic immunized mice were adoptively transferred to NSG (NOD/SCID/IL2Rγnull) mice bearing human ovarian or pancreatic tumors which were HER2+, HLA-A2+.

Administration of the NeuVax vaccination resulted in a specific, delayed-type hypersensitivity (DTH) reaction and in the induction of E75 specific CD8+ T cells that express PD-1 (programmed T-cell death protein). Both ovarian and pancreatic tumor growth rate was significantly reduced in NSG mice that received the CD8+ T cells from NeuVax-immunized mice compared to those receiving CD8+ T cells from control mice. Additionally, PD-1 was identified on activated CD8+ T cells.

“The findings from this preclinical mouse model provide scientific bases about the efficacy of NeuVax vaccination in hampering ovarian and pancreatic tumor progression by showing both DTH reactions and NeuVax specific CD8+ T cells,” said Bijan Nejadnik, M.D., Executive Vice President and Chief Medical Officer. “Importantly, the expression of PD-1 on activated CD8+ T cells suggests an opportunity to investigate the efficacy of NeuVax in combination with PD-1 inhibitors. We appreciate the work and dedication on this study run by our partners at theUniversity of Torino in Italy.” (Original Source)

Shares of Galena are currently trading at $0.355, up $0.001 or 0.42%. GALE has a 1-year high of $2.49 and a 1-year low of $0.28. The stock’s 50-day moving average is $0.43 and its 200-day moving average is $1.09.

On the ratings front, Galena has been the subject of a number of recent research reports. In a report issued on August 16, FBR analyst Vernon Bernardino reiterated a Buy rating on GALE, with a price target of $2.00, which implies an upside of 471% from current levels. Separately, on August 11, Maxim’s Jason McCarthy reiterated a Buy rating on the stock and has a price target of $1.00.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Jason McCarthy have a total average return of -14.9% and 0.1% respectively. Bernardino has a success rate of 28% and is ranked #4012 out of 4143 analysts, while McCarthy has a success rate of 36.5% and is ranked #2465.

Galena Biopharma, Inc. engages as a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral (fentanyl) sublingual tablets and Zuplenz (ondansetron) oral soluble film.